Bimzelx® (bimekizumab-bkzx)

Help Us Better Understand the Effects of Bimzelx® in Pregnancy

Many people need to take medication during pregnancy to appropriately manage a chronic health condition. In some cases, avoiding or stopping medication use during pregnancy may be more harmful than taking medication. Yet fewer than 10% of medications have enough information to determine their safety for use in pregnancy — this is where you come in!

MotherToBaby is currently enrolling people who are pregnant in a study examining the use of Bimzelx® (bimekizumab-bkzx) to treat psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis during pregnancy.

> *"There is a huge need to generate more info for all of the drugs that people who are pregnant need to take."*
>
> *--- Christina Chambers, PhD, MPH, Lead Investigator, MotherToBaby Pregnancy Studies*

Are you currently pregnant? Did you take Bimzelx® at any point in your current pregnancy? If you answered "yes" to both of these questions, then you have the opportunity to help us learn more about Bimzelx® use in pregnancy.

Will you take the step and become our partner? Make an impact on the health of future families today by joining our Bimzelx® & Pregnancy Study!

JOIN A STUDY

REFER A PATIENT

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, October 3, 2024.

Bimzelx® (bimekizumab-bkzx)

We're Collecting Info on BOOSTRIX When Taken in Pregnancy

MotherToBaby is currently enrolling pregnant people who received (or plan to receive) the BOOSTRIX Tdap vaccine in an observational study. This vaccine is recommended during the 3rd trimester of pregnancy to prevent pertussis (whooping cough) in infants under the age of 2 months. If you have already received the Tdap vaccine during the third trimester of your pregnancy or you plan to do so, we invite you to join our observational study. Participation involves providing information about your pregnancy and your baby's development for a certain period of time after birth.

Please note that we will **not** ask you to receive the Tdap vaccine as part of the study; we are solely interested in gathering data from those who have already chosen to receive BOOSTRIX during the third trimester of pregnancy. If you meet this criteria, you may be eligible to participate.

JOIN NOW
REFER A PATIENT

Questions?

To connect with our research team, please contact us at

Phone | 877.311.8972
Email | mothertobaby@health.ucsd.edu

We're open Monday – Thursday from 7am – 7pm and Friday 7am – 6pm Pacific, excluding public holidays.

You can also visit our Frequently Asked Questions to learn more about participating in our studies.

How Our Studies Work



Parent-To-Be Enrolls in Study



We Gather Info about the Pregnancy



Discoveries & Insights Gained

What's Involved?

Our BOOSTRIX study includes:
• 1-3 phone interviews during your pregnancy and at least 1 interview after you have your baby.
• Your permission to obtain a copy of your medical records from your healthcare provider for your pregnancy and for your child through 1 year of age.

All the information you provide will be kept confidential. Your privacy is important to us. We comply with strict regulations and laws set forth by state and federal agencies as well as the Institutional Review Board (IRB) at the University of California, San Diego, who oversees and monitors our research. Since we ask for your permission to obtain medical records, we will also give you detailed information on how this data will be used and how we will protect your privacy.



What is a MotherToBaby Pregnancy Study?

MotherToBaby Pregnancy Studies is a research program seeking to understand how certain medications, vaccines, or health conditions may affect pregnancy. Our research will help people who are pregnant and/or breastfeeding and health providers make informed treatment decisions. All of our studies are observational: we will never ask someone to take or change any aspect of their current health routine.

Who Leads MotherToBaby Pregnancy Studies?

Christina Chambers, PhD, MPH is the lead investigator for MotherToBaby Pregnancy Studies, which are coordinated by UC San Diego's Center for Better Beginnings. She is a world-renowned perinatal epidemiologist and a Professor of Pediatrics and Family and Preventive Medicine at the UC San Diego. Her interests are in the areas of birth defects and other pregnancy outcomes, with a special focus on exposures that can cause birth defects.

"Every person deserves to know if their health conditions or the medication they need to take could affect their baby during pregnancy. We are committed to bringing you better information for healthier outcomes."

– Christina Chambers, PhD, MPH



If you are interested in joining the study, please submit your interest below. Our research team will contact you to see if you qualify. Your information is confidential.

If you are a health professional, please fill out the Refer a Patient form and we will contact your patient to see if they qualify. Your information is confidential.

The BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine) Pregnancy Study conducted by MotherToBaby and is sponsored by GSK.



Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, October 3, 2024.

Bimzelx® (bimekizumab-bkzx)

We're Collecting Info on Kesimpta® When Taken in Pregnancy

MotherToBaby is currently enrolling participants into an observational study examining the use of Kesimpta® (ofatumumab) when taken within 5 1/2 months before or during pregnancy. Our studies are strictly observational, which means we will never ask you to take any new medicines, experimental drugs or to change any part of your healthcare routine. If you enroll, you'll simply be followed by our team through the remainder of your pregnancy, and your baby will be followed for a period of time after birth. Eligible moms-to-be who enroll in the study may receive up to $250 to compensate them for the time they spend completing study activities.

Our goal is to provide parents and their health providers with the evidence-based information that they need to make

more informed healthcare decisions during pregnancy. To do that, we need your help. If you have multiple sclerosis and have taken Kesimpta® (ofatumumab) at any point in your current pregnancy, or shortly prior to pregnancy, you may qualify for this important study.

JOIN NOW
REFER A PATIENT

Questions?

To connect with our research team, please contact us at

Phone | 877.311.8972
Email | mothertobaby@health.ucsd.edu

We're open Monday – Thursday from 7am – 7pm and Friday 7am – 6pm Pacific, excluding public holidays.

You can also visit our Frequently Asked Questions to learn more about participating in our studies.

How Our Studies Work



Parent-To-Be Enrolls in Study



We Gather Info about the Pregnancy



Discoveries & Insights Gained

What’s Involved?

Our Kesimpta® (ofatumumab) study includes:
• 1-3 phone interviews during your pregnancy and at least 1 interview after you have your baby.
• Your permission to obtain a copy of your medical records from your healthcare provider for your pregnancy and for your child through 1 year of age.

• An opportunity to receive a specialized, non-invasive exam of your baby with a study doctor
• An online neurodevelopmental assessment that can also provide insight into the child's development at approximately 12 months of age

Thank You for Participating: Compensation for Moms Who Take Part

We know your time is valuable. To thank you for the time you'll be spending on study activities, you will receive $50 for each activity listed below.

Celebrated Study Milestones – Up to $250 in total compensation!

- $50 for completing our enrollment interview and returning the signed form to release your pregnancy-related medical records to the study
- $50 for completing the phone interview that will take place around the 20-week mark of your pregnancy
- $50 for completing the phone interview that will take place around the 32-week mark of your pregnancy
- $50 for completing the phone interview that will take place after the end of your pregnancy and returning the signed form to release to the study the medical records related to the outcome of your pregnancy
- $50 for completing the child development questionnaire (the Ages and Stages Questionnaire) and returning the signed form to release your child's pediatric medical records to the study

✔ You will be compensated at the time each study activity is completed

✔ There's no penalty if you choose not to complete every study activity

✔ Participation in our study never changes your med

All the information we request will be kept confidential. Your privacy is important to us. We comply with strict regulations
and laws set forth by state and federal agencies as well as the Institutional Review Board (IRB) at the University of
California, San Diego, who oversees and monitors our research. Since we ask for your permission to obtain medical
records, we will also give you detailed information on how this data will be used and how we will protect your privacy.



What is a MotherToBaby Pregnancy Study?

MotherToBaby Pregnancy Studies is a research program seeking to understand how certain medications, vaccines, or health conditions may affect pregnancy. Our research will help people who are pregnant and/or breastfeeding and health providers make informed treatment decisions. All of our studies are observational: we will never ask someone to take or change any aspect of their current health routine.

Who Leads MotherToBaby Pregnancy Studies?

Christina Chambers, PhD, MPH is the lead investigator for MotherToBaby Pregnancy Studies, which are coordinated by UC San Diego's Center for Better Beginnings. She is a world-renowned perinatal epidemiologist and a Professor of Pediatrics and Family and Preventive Medicine at the UC San Diego. Her interests are in the areas of birth defects and other pregnancy outcomes, with a special focus on exposures that can cause birth defects.

"Every person deserves to know if their health conditions or the medication they need to take could affect their baby during pregnancy. We are committed to bringing you better information for healthier outcomes."

– Christina Chambers, PhD, MPH



If you are interested in joining the study, please submit your interest below. Our research team will contact you to see if you qualify. Your information is confidential.

If you are a health professional, please fill out the Refer a Patient form and we will contact your patient to see if they qualify. Your information is confidential.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, October 3, 2024.

Bimzelx® (bimekizumab-bkzx)

This study is now closed to recruitment.

Thank you for your interest, but unfortunately we are no longer enrolling participants in this study. However, you may be eligible to participate in a study. Fill out your information using our Join a Study form, and a member of our team will contact you.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, October 3, 2024.

Bimzelx® (bimekizumab-bkzx)

We're Collecting Info on Adbry® When Taken in Pregnancy

MotherToBaby is currently enrolling participants into an observational study examining the use of Adbry® (tralokinumab-ldrm) when taken during pregnancy. **Our research is by observation only—we will not ask you to take or change any medications.** If you join our Adbry® study, our team will simply collect some information about your pregnancy and your baby's development for a period of time after birth.

> *"Help us improve the ability for pregnant people and their healthcare providers to make more informed treatment decisions by joining our Adbry® & Pregnancy Study."*
>
> *— Christina Chambers, PhD, MPH, Lead Investigator, MotherToBaby Pregnancy Studies*

Our study includes:

- 1-3 phone interviews during your pregnancy and at least 1 interview after you have your baby.
- Your permission to obtain a copy of your and your baby's medical records from your healthcare providers.
- An opportunity to receive a specialized, non-invasive exam of your baby with a study doctor.
- A neurodevelopmental assessment that can also provide insight into the child's development at approximately 4 months and 12 months of age

If you have moderate-to-severe eczema (atopic dermatitis) and have taken Adbry® (tralokinumab-ldrm) at any point in your current pregnancy or 3 months prior to pregnancy, you may qualify for this important study. Will you take the

next step and help us learn more about the use of Adbry® (tralokinumab-ldrm) during pregnancy?

JOIN A STUDY

REFER A PATIENT

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, October 3, 2024.